GW sets its sights on Zogenix and a new Epidiolex use
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
US regulators on track for another strong year
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.
GW’s Dravet lock looks broken as Zogenix data scores
Battle in a rare form of epilepsy queued up following positive phase III trial.
Upcoming events – Zogenix and Mallinckrodt look to rare diseases
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.